BridgeBio Pharma LLC Signs Joint Collaboration Agreement with Cincinnati Children’s to Accelerate Development of Genetic Disease Therapeutics

PALO ALTO, Calif. and CINCINNATI, Nov. 12, 2018 /PRNewswire/ — BridgeBio Pharma LLC and Cincinnati Children’s Hospital Medical Center today announced they are entering into a research collaboration to identify and develop genetic disease therapies. This partnership will combine BridgeBio’s strengths in therapeutic development for diseases of high unmet need with Cincinnati Children’s world-class researchers and clinicians. As a global research center of excellence, Cincinnati Children’s represents an ideal partner for BridgeBio and reinforces BridgeBio’s commitment to collaborating with leading researchers toward the mutual goal of discovering new therapies targeting genetic diseases at the source.

“BridgeBio is privileged to partner with leading experts at Cincinnati Children’s, an institution whose impact on science and patients we admire. We hope we can help advance the mission by partnering to move therapies forward to patients,” said Neil Kumar, co-founder and CEO of BridgeBio.

“We are excited to launch this new alliance with BridgeBio to bring new and innovative therapies to some of the most vulnerable patients impacted by rare and complex genetic diseases,” said Margaret Hostetter, MD, Chief Medical Officer of Cincinnati Children’s and Director, Cincinnati Children’s Research Foundation.

“This collaboration exemplifies Cincinnati Children’s commitment to accelerating discoveries towards commercialization through win-win academic-industry partnerships,” added Mike Pistone, Director of Acceleration for Cincinnati Children’s Innovation Ventures, the group managing this program.

Under the terms of the agreement, BridgeBio will have the opportunity to sponsor and collaboratively develop selected research programs. The agreement represents a flexible model that facilitates accelerated genetic disease research.

About BridgeBio Pharma

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. The company bridges remarkable advancements in genetic science with the entrepreneurial engine required to rapidly create lifesaving medicines for patients with unmet needs. Founded in 2015 by a team of industry veterans, the company has built a robust portfolio of 19 transformative drugs ranging from pre-clinical to late stage development in multiple therapeutic areas including oncology, cardiology, dermatology, and endocrinology. The company’s focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. For additional information, visit

News Archive


Hope through rigorous science - medicines with transformative potential for patients with unmet needs.

Our Mission